ES8705459A1 - Procedimiento para la obtencion de nuevos compuestos este- roides - Google Patents

Procedimiento para la obtencion de nuevos compuestos este- roides

Info

Publication number
ES8705459A1
ES8705459A1 ES544768A ES544768A ES8705459A1 ES 8705459 A1 ES8705459 A1 ES 8705459A1 ES 544768 A ES544768 A ES 544768A ES 544768 A ES544768 A ES 544768A ES 8705459 A1 ES8705459 A1 ES 8705459A1
Authority
ES
Spain
Prior art keywords
spiroxanes
analogues
preparation
pharmaceutical compositions
open ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES544768A
Other languages
English (en)
Other versions
ES544768A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES544768A0 publication Critical patent/ES544768A0/es
Publication of ES8705459A1 publication Critical patent/ES8705459A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

METODO DE OBTENER NUEVOS COMPUESTOS ESTEROIDES. CONSISTE EN TRATAR UN COMPUESTO DE FORMULA (II) CON UN AGENTE DE OXIDACION, EN PRESENCIA DE UN DISOLVENTE ORGANICO INERTE, A PRESION NORMAL Y A UNA TEMPERATURA ENTRE C10 Y 50JC, PARA OBTENER NUEVOS COMPUESTOS ESTEROIDES DE FORMULA (I) DONDE A-A- SIGNIFICA EL GRUPO -CH2-CH2- O CHFCH-; R1 ES H; R2 ES UN ALCOXI INFERIOR-CARBONILO A-ORIENTADO Y OTROS; X ES DOS ATOMOS DE HIDROGENO U OXO; E Y1 E Y2 JUNTOS FORMAN EL PUENTE OXIGENO -O- Y OTROS. TIENEN APLICACIONES FARMACEUTICAS COMO DIURETICOS.
ES544768A 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides Expired ES8705459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (2)

Publication Number Publication Date
ES544768A0 ES544768A0 (es) 1987-05-01
ES8705459A1 true ES8705459A1 (es) 1987-05-01

Family

ID=4223123

Family Applications (4)

Application Number Title Priority Date Filing Date
ES531517A Granted ES531517A0 (es) 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides
ES544768A Expired ES8705459A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544769A Expired ES8705460A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544770A Expired ES8705461A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES531517A Granted ES531517A0 (es) 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES544769A Expired ES8705460A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544770A Expired ES8705461A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Country Status (23)

Country Link
US (1) US4559332A (es)
EP (1) EP0122232B1 (es)
JP (1) JPS59231100A (es)
AR (4) AR241918A1 (es)
AT (1) ATE39256T1 (es)
AU (1) AU565017B2 (es)
CA (1) CA1220781A (es)
DD (2) DD251144A5 (es)
DE (2) DE3475622D1 (es)
DK (1) DK163988C (es)
ES (4) ES531517A0 (es)
FI (1) FI77669C (es)
GR (1) GR81834B (es)
HU (1) HU191406B (es)
IE (1) IE57541B1 (es)
IL (1) IL71504A (es)
LU (1) LU91072I2 (es)
NL (1) NL300144I1 (es)
NO (1) NO159800C (es)
NZ (1) NZ207826A (es)
PH (1) PH19997A (es)
PT (1) PT78413B (es)
ZA (1) ZA842710B (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
DK0526642T3 (da) * 1991-01-29 1998-10-19 Shionogi & Co Triterpenderivat
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
ES2167571T3 (es) * 1995-06-07 2002-05-16 Searle & Co Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
EP1167381A3 (en) * 1995-12-11 2004-09-29 G.D. Searle & Co. Process for preparation of 7 alpha-carboxyl 9,11-epoxy steroids and Intermediates useful therein
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
PT973791E (pt) 1995-12-11 2007-09-26 Searle Llc Processo para a preparação de um composto epoxi
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
EP1148061B1 (en) * 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
DK0944644T3 (da) 1996-12-11 2003-02-03 Searle & Co Fremgangsmåde til fremstilling af 3-keto-7-alfa-alkoxycarbonyl-delta-4,5-steroider og mellemprodukter, som er nyttite derfor
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
ZA9711038B (en) * 1996-12-11 1999-01-25 Searle & Co Spr process for preparation of 9,11-Epoxy steroids and intermediates useful therein
US6368835B1 (en) * 1998-05-29 2002-04-09 Kyowa Hakko Kogyo Co., Ltd. Process for producing a lactone using corynebacterium sp. NK-1 (FERM BP-6329)
JP2002529405A (ja) * 1998-11-06 2002-09-10 ジー・ディー・サール・アンド・カンパニー 心臓血管系疾患による発病率及び死亡率減少のためのアンギオテンシン変換酵素阻害薬及びアルドステロン拮抗薬の併用療法
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DK1140185T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
EP1140186B1 (en) * 1998-12-23 2003-06-04 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
CN1342091A (zh) * 1998-12-23 2002-03-27 G.D.瑟尔有限公司 心血管指征的联合用药
MXPA01006472A (es) * 1998-12-23 2004-03-10 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
DK1140184T3 (da) * 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
PT1140190E (pt) 1998-12-23 2003-02-28 Searle Llc Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares
EP1342475A1 (en) 1998-12-23 2003-09-10 G.D. Searle LLC. Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
ATE293977T1 (de) * 1999-12-08 2005-05-15 Pharmacia Corp Nanopartikelzusammensetzungen enthaltend eplerenon
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
BR0008057A (pt) * 1999-12-08 2002-04-23 Pharmacia Corp Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
IL144757A0 (en) * 1999-12-08 2002-06-30 Pharmacia Corp Eplerenone crystalline form
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
EP1280533A2 (en) * 2000-05-11 2003-02-05 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US20020123485A1 (en) * 2000-07-27 2002-09-05 Alexander John C. Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
WO2002017895A2 (en) * 2000-08-28 2002-03-07 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
AU2002241768A1 (en) * 2000-10-30 2002-06-18 Pharmacia Corporation Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
CN100408099C (zh) * 2000-11-09 2008-08-06 阿斯特拉曾尼卡有限公司 含有嵌段共聚物的口服药物组合物
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
EP1455795A1 (en) 2001-12-12 2004-09-15 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
KR20040091141A (ko) * 2002-03-18 2004-10-27 파마시아 코포레이션 알도스테론 수용체 길항물질 및 니코틴산 또는 니코틴산유도체의 혼합물
WO2003080069A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
MXPA04009037A (es) * 2002-03-20 2005-01-25 Pharmacia Corp Formulacion de eplerenona de almacenamiento estable.
CN1653081A (zh) * 2002-03-22 2005-08-10 法玛西雅公司 甾族化合物的c－17螺甾内酯化和6,7氧化
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
BR0313523A (pt) * 2002-08-16 2005-06-28 Upjohn Co Intermediários do esteróide 5-androsten-3(beta)-ol e processos para a sua preparação
CA2504745A1 (en) * 2002-11-06 2004-05-27 Pharmacia & Upjohn Company Llc Processes for preparing 7-carboxy substituted steroids
ATE354583T1 (de) * 2002-11-07 2007-03-15 Pharmacia & Upjohn Co Llc Verfahren zur herstellung c-7 substituierter 5- androstene
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CN1934126A (zh) * 2004-03-22 2007-03-21 法玛西雅厄普约翰有限责任公司 9,11环氧甾族化合物的改进制备方法
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
EP2124959A4 (en) * 2006-12-21 2011-09-14 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
SG176010A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP3689364A1 (en) * 2010-02-08 2020-08-05 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
CA2796307A1 (en) 2010-05-10 2011-11-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
NZ710574A (en) 2013-02-14 2017-11-24 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
ES2699923T3 (es) 2014-10-17 2019-02-13 Ind Chimica Srl Proceso para la preparación de 7alfa-(metoxicarbonil)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactona, un intermedio útil para la síntesis de moléculas con actividad farmacológica
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
NL300144I2 (nl) 2004-06-01
AR242222A1 (es) 1993-03-31
PT78413A (en) 1984-05-01
ES8705460A1 (es) 1987-05-01
DD233375A5 (de) 1986-02-26
JPS59231100A (ja) 1984-12-25
ES8602846A1 (es) 1985-12-01
NO159800C (no) 1989-02-08
AU565017B2 (en) 1987-09-03
ES544768A0 (es) 1987-05-01
ES544769A0 (es) 1987-05-01
FI77669B (fi) 1988-12-30
ATE39256T1 (de) 1988-12-15
LU91072I2 (fr) 2004-04-07
CA1220781A (en) 1987-04-21
IE840906L (en) 1984-10-13
DE122004000012I1 (de) 2012-05-16
EP0122232B1 (de) 1988-12-14
IL71504A (en) 1987-07-31
JPH0212479B2 (es) 1990-03-20
FI841400A0 (fi) 1984-04-09
NZ207826A (en) 1986-07-11
AU2685384A (en) 1984-10-18
IE57541B1 (en) 1992-10-07
AR241918A1 (es) 1993-01-29
AR242223A1 (es) 1993-03-31
DE122004000012I2 (de) 2006-06-08
DK163988C (da) 1992-09-21
IL71504A0 (en) 1984-07-31
DK189484A (da) 1984-10-14
ES544770A0 (es) 1987-05-01
NL300144I1 (nl) 2004-06-01
HU191406B (en) 1987-02-27
DK163988B (da) 1992-04-27
GR81834B (es) 1984-12-12
PT78413B (en) 1986-08-22
ES531517A0 (es) 1985-12-01
EP0122232A1 (de) 1984-10-17
AR242221A1 (es) 1993-03-31
NO841465L (no) 1984-10-15
FI77669C (fi) 1989-04-10
ZA842710B (en) 1984-11-28
DD251144A5 (de) 1987-11-04
FI841400L (fi) 1984-10-14
PH19997A (en) 1986-08-28
ES8705461A1 (es) 1987-05-01
DE3475622D1 (en) 1989-01-19
DK189484D0 (da) 1984-04-12
NO159800B (no) 1988-10-31
US4559332A (en) 1985-12-17

Similar Documents

Publication Publication Date Title
AR245718A1 (es) Procedimiento para preparar un compuesto de imidazo (4,5-b)-piridina
ES8705460A1 (es) Procedimiento para la obtencion de nuevos compuestos este- roides
ES8304095A1 (es) Un procedimiento para la preparacion de derivados de quinazolina.
ES8301980A1 (es) Procedimiento para la preparacion de 8-arilalcohil-3-fenil-3-nortropanoles .
ES435949A1 (es) Procedimiento de prepracion de acidos 4-aril-4-oxo-2-meti- len-butricos.
ES8703437A1 (es) Procedimiento para la preparacion de 4h-3,1-benzoxazin-4-- onas y compuestos relacionados
ES2079632T3 (es) Procedimiento para producir n-fosfonometilglicina.
ES8706608A1 (es) Un procedimiento para preparar derivados de arilciclobutilalquilamina
Majeski et al. Controlled potential oxidation of anthracene in acetonitrile. II
MX3300E (es) Procedimiento para la obtencion de una composicion insecticida que contiene como compuestos activos (+)-cis, trans crisantematos
ES8801666A1 (es) Un procedimiento para la prepracion de derivados de acidos griseolicos.
ES8609323A1 (es) Un procedimiento para la preparacion de hexahidro-arilquinolizinas sustituidas.
ES8607960A1 (es) Procedimiento para preparar acidos aroil-benzofuran y benzo-tiofen-aceticos y-propionicos
ES8106516A1 (es) Procedimiento de preparacion de nuevos derivados halovinca- monas y de sus sales de adicion acidas farmaceuticamente aceptables e isomeros opticamente activos de los mismos
ES8601089A1 (es) Procedimiento para la preparacion de compuestos antipsoria- ticos naftalenicos
KR840006766A (ko) 항 진균제의 제조방법
ES8205215A1 (es) Un procedimiento para la preparacion de nuevos derivados del acido acetico.
RO70855B (ro) Procedeu de obtinere a unor sulfoxizi farmacologic activi
ES265738A1 (es) Un procedimiento para la preparaciën de un dinitrato de alcohileno diol
ES8204723A1 (es) Un procedimiento para la preparacion de 4-alcohilo inferior-3-fenoxipiridina-1-oxido
ATE10279T1 (de) Herstellung von furanverbindungen und katalytisches system.
ES464352A1 (es) Procedimiento para la preparacion de acidos fenilalquilcarboxilicos.
ES8403482A1 (es) Procedimiento para la preparacion de nuevas piridobenzodiazepinonas.
ES8801636A1 (es) Un procedimiento para preparar nuevos derivados de imidazol
SE7604245L (sv) Nya fungicida blandningar

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20070120